Next Gen Diagnostics Announces Agreement to Develop Sequence-Based Susceptibility Determination of cefiderocol

PRESS RELEASE
Written By Casey-Drew Williams

Next Gen Diagnostics (NGD), a world leader in the development of validated machine learning models for whole genome sequence-based determination of bacterial susceptibility to antibiotics, announces an agreement with Shionogi & Co., Ltd. (Shionogi) to develop models to predict susceptibility to cefiderocol. Shionogi is a global research-driven pharmaceutical company based in Japan and is the developer of cefiderocol.

Casey-Drew Williams
Previous

Next Gen Diagnostics Announces New York State Department of Health’s Wadsworth Center Has Joined the NGD Cefiderocol Data Consortium for the Sequencing-Based Determination of Cefiderocol Resistance
Next

Next Gen Diagnostics Announces Opening of a US Sequencing and Bioinformatics Laboratory in Cambridge, Massachusetts